Repertoire Immune Medicines to Present at Oppenheimer 31st Annual Healthcare Conference

Repertoire Immune Medicines to Present at Oppenheimer 31st Annual Healthcare Conference




Repertoire Immune Medicines to Present at Oppenheimer 31st Annual Healthcare Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Repertoire Immune Medicines, a clinical-stage biotech company creating a new category of immune therapies for cancer, autoimmunity and infectious disease, today announced that John Cox, Chief Executive Officer, will present at the Oppenheimer 31st Annual Healthcare Conference on Thursday, March 18, 2021, at 10:00 a.m. ET.

About Repertoire Immune Medicines

Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat cancer, as well as autoimmune and infectious disease. The company is founded on the belief that the repertoire of T cell receptor (TCR)-antigen codes that drive health and disease represents one of the greatest opportunities for innovation in medical science. Repertoire scientists created and developed the DECODE™ and DEPLOY suite of technologies, which allow in-depth characterization of TCR-antigen pairs, and the ability to rationally design and develop novel targeted immune medicines.

From its sites in Cambridge, Mass., and Zurich, Switzerland, Repertoire’s team of more than 120 is creating a new category of immune medicines enabled from its DECODE discovery platform. The company’s first product in the clinic is a novel multiclonal T cell therapy consisting of naïve, rare T cells derived from the peripheral blood, activated against a curated set of antigens and armed with a proprietary cytokine payload. Repertoire is in clinical-stage immuno-oncology development today, targeting metastatic solid tumors. In the field of autoimmunity, Repertoire is using its proprietary platform to discover novel epitopes and TCRs from patients with type 1 diabetes. The company is also using its DECODE platform to discover infectious disease antigens and responding T cell clones.

To learn more about Repertoire Immune Medicines, please visit our website: www.repertoire.com and follow us on LinkedIn and Twitter.

Contacts

Investor Contact:
Kendall Investor Relations

Carlo Tanzi, Ph.D.

ctanzi@kendallir.com

Media Contact:
Scient Public Relations

Lindsay G. Deefholts

ldeefholts@scientpr.com